Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2296-2305

  Buckley, Patrick G ^a,b   Das, Sudipto ^a,b   Bryan, Kenneth ^a,b   Watters, Karen M ^a,b   Alcock, Leah ^a,b   Koster, Jan ^c   Versteeg, Rogier ^b   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

DNA hypermethylation; MeDIP; MYCN; neuroblastoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; CRH1A GENE; CSPG3 GENE; DNA METHYLATION; EIF4G1 GENE; ELFN2 GENE; EPIGENETICS; FXR1 GENE; GANGLIONEUROMA; GENE ACTIVATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENOMICS; HUMAN; HUMAN CELL; NEUROBLASTOMA; NF1B GENE; NME2 GENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SPTBN2 GENE; TELOMERE; UBE2D3 GENE;

AZACITIDINE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HUMANS; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; TELOMERE;

EID: 79953172603     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25584     Document Type: Article

References (48)

1. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16. (Pubitemid 37328872)
2. Esteller M, Corn PG, Baylin SB, Herman JG,. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9. (Pubitemid 32695003)
3. Esteller M,. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-40. (Pubitemid 34983479)
4. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M,. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004; 96: 1208-19. (Pubitemid 39232712)
5. Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001; 20: 7573-7. (Pubitemid 33086917)
6. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM,. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 2000; 35: 603-7.
7. van Noesel MM, van Bezouw S, Voute PA, Herman JG, Pieters R, Versteeg R,. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003; 38: 226-33. (Pubitemid 37259639)
8. Liu J, Bi G, Wen P, Yang W, Ren X, Tang T, Xie C, Dong W, Jiang G,. Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 2007; 4: 59-63.
9. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL,. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004; 10: 8493-500. (Pubitemid 40053415)
10. Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC,. Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008; 50: 29-32. (Pubitemid 350234261)
11. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D,. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37: 853-62. (Pubitemid 41077111)
12. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Allemanni G, Bonassi S, Tonini GP, Romani M,. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005; 24: 5619-28. (Pubitemid 43119355)
13. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T,. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007; 247: 253-8. (Pubitemid 46240612)
14. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ,. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-9.
15. Hitchins MP, Lin VA, Buckle A, Cheong K, Halani N, Ku S, Kwok CT, Packham D, Suter CM, Meagher A, Stirzaker C, Clark S, et al. Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res 2007; 67: 9107-16. (Pubitemid 47535896)
16. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW,. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 2008; 68: 8616-25.
17. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP,. CpG island hypermethylation in human astrocytomas. Cancer Res 2010; 70: 2718-27.
18. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, Sarkar A, Barasch J, Vuononvirta R, Jones C, Pritchard-Jones K, Royer-Pokora B, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet 2009; 5: e1000745.
19. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B,. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009; 4: e4830.
20. Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, Nair P, Brothman AR, Stallings RL,. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005; 44: 305-19. (Pubitemid 41397100)
21. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S, Bray I, Watters KM, Higgins D, Stallings RL,. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-Box motifs and regions of DNA hypermethylation. PLoS One 2009; 4: e8154.
22. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D,. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-66. (Pubitemid 46514772)
23. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA,. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
24. Kin T, Ono Y,. Idiographica: a general-purpose web application to build idiograms on-demand for human, mouse and rat. Bioinformatics 2007; 23: 2945.
25. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T,. BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21: 4067-8. (Pubitemid 41631851)
26. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS,. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010; 126: 2012-24.
27. Morison IM, Ramsay JP, Spencer HG,. A census of mammalian imprinting. Trends Genet 2005; 21: 457-65. (Pubitemid 40981795)
28. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D,. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006; 166: 74-81.
29. Nair PN, McArdle L, Cornell J, Cohn SL, Stallings RL,. High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genet Cytogenet 2007; 174: 100-10. (Pubitemid 46604833)
30. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, Burton J, Cox TV, Davies R, Down TA, Haefliger C, Horton R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38: 1378-85. (Pubitemid 44837559)
31. Ng LJ, Cropley JE, Pickett HA, Reddel RR, Suter CM,. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res 2009; 37: 1152-9.
32. Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M,. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 2003; 22: 401-11. (Pubitemid 36194336)
33. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS,. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993; 8: 855-65. (Pubitemid 23087416)
34. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ,. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009; 11: 903-8.
35. Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, Lenhof HP, Meese E,. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 2007; 120: 2538-44. (Pubitemid 46651273)
36. Kano S, Miyajima N, Fukuda S, Hatakeyama S,. Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res 2008; 68: 5572-80.
37. Ambros IM, Zellner A, Stock C, Amann G, Gadner H, Ambros PF,. Proof of the reactive nature of the Schwann cell in neuroblastoma and its clinical implications. Prog Clin Biol Res 1994; 385: 331-7.
38. Mora J, Cheung NK, Juan G, Illei P, Cheung I, Akram M, Chi S, Ladanyi M, Cordon-Cardo C, Gerald WL,. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 2001; 61: 6892-8. (Pubitemid 32896515)
39. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL,. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 2002; 62: 7357-63. (Pubitemid 36032697)
40. Cairns P,. 5'-azacytidine expression arrays. Methods Mol Biol 2009; 507: 165-74.
41. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P,. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006; 66: 5021-8. (Pubitemid 43844922)
42. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T, Sasaki Y, Ohmura T, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat 2010; 122: 699-710.
43. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, Westra W, Van Criekinge W, Sidransky D,. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009; 15: 1184-91.
44. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C,. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001; 10: 1413-19. (Pubitemid 32640670)
45. Issa JP, Kantarjian HM,. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-46.
46. Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, Squire JA,. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One 2008; 3: e2834.
47. Kwong J, Lo KW, Chow LS, To KF, Choy KW, Chan FL, Mok SC, Huang DP,. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 2005; 7: 67-74. (Pubitemid 40209472)
48. Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R,. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res 2005; 65: 3136-45. (Pubitemid 40524594)